Related Experiment Video
Updated: May 10, 2026
07:37
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
Psoriatic arthritis: current therapy and future directions
DoQuyen Huynh1, Arthur Kavanaugh
1University of California, Division of Rheumatology, 9444 Medical Center Dr. Suite, La Jolla, San Diego, California, CA 92093-0943, USA. d4huynh@ucsd.edu
Expert Opinion on Pharmacotherapy
|July 3, 2013
Summary
Psoriatic arthritis (PsA) management has advanced with tumor necrosis factor inhibitors (TNFi). Further research is needed for PsA-specific outcomes, early treatment, advanced imaging, and alternative therapies.
Area of Science:
- Rheumatology
- Immunology
- Dermatology
Background:
- Psoriatic arthritis (PsA) is a complex autoimmune condition distinct from rheumatoid arthritis.
- PsA involves skin manifestations and has unique disease drivers.
- Therapeutic responses in PsA differ from those in rheumatoid arthritis.
Purpose of the Study:
- To review recent advancements in PsA treatment.
- To focus on current disease-modifying anti-rheumatic drugs (DMARDs) and novel targeted agents for PsA.
- To highlight key research areas and unanswered questions in PsA management.
Main Methods:
- Literature review of OVID and PubMed databases.
- Focus on articles published in the past 10 years.
- Analysis of major concepts in current PsA therapeutics.
Main Results:
- Tumor necrosis factor inhibitors (TNFi) have significantly improved PsA management.
- PsA research is increasingly mirroring rheumatoid arthritis (RA) research.
- Key areas for future PsA research include outcome measures, treat-to-target strategies, advanced imaging, and combination therapies.
Conclusions:
- TNFi therapy has transformed PsA care.
- There is a critical need for PsA-specific outcome measures.
- Future research should address early intervention, sensitive imaging, and alternative treatments for TNFi-intolerant or non-responsive patients.
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:21Rheumatic Heart Disease III: Medical Management
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
01:11Genome-wide Association Studies-GWAS
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...